THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.9] ID: TIP-MED-000241

Dutasteride (Dual Type-1/Type-2 5-Alpha-Reductase Inhibitor)

Active Ingredient / Scientific Identity: Dutasteride • Class: Dual Type-1 and Type-2 5-Alpha-Reductase Inhibitor

⚖️ Compare Profile
Generic / Entity NameDutasteride (Dual Type-1/Type-2 5-Alpha-Reductase Inhibitor) ([12.9])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassDual Type-1 and Type-2 5-Alpha-Reductase Inhibitor
Available Dosage FormsSoft Gelatin Capsule / Tablet: 0.5 mg.
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: No dose adjustment required in renal impairment (<0.1% excreted unchanged in urine). • Hepatic: Metabolised extensivel
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Dutasteride (Dual Type-1/Type-2 5-Alpha-Reductase Inhibitor) (TIP-MED-000241, Reference Code [12.9]) is classified under Urological & Renal Stone Medicines (Ch 12) as a Dual Type-1 and Type-2 5-Alpha-Reductase Inhibitor. Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.9], p. 159): Duprost, Veltride, Dutas (FDC with Tamsulosin: Urimax-D, Veltam-Plus) — Strengths & Dosage Forms: Soft Gelatin Capsule / Tablet: 0.5 mg.
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.9], p. 159): Duprost, Veltride, Dutas (FDC with Tamsulosin: Urimax-D, Veltam-Plus) — Strengths & Dosage Forms: Soft Gelatin Capsule / Tablet: 0.5 mg.
Dosage Forms & Available Strengths:
Soft Gelatin Capsule / Tablet: 0.5 mg.
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Inhibits both Type-1 and Type-2 isoenzymes of 5-alpha-reductase -> blocks conversion of testosterone to dihydrotestosterone (DHT), reducing serum DHT by >90%.

4. Therapeutic Indications & Evidence-Supported Uses

  • Moderate-to-severe benign prostatic hyperplasia (reduces prostate volume by ~25-30% and prevents acute urinary retention/BPH surgery)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adult: 0.5 mg PO once daily (requires 3-6 months of continuous therapy for maximal prostate shrinkage). • Paediatric: Contraindicated in children and adolescents.

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: No dose adjustment required in renal impairment (<0.1% excreted unchanged in urine). • Hepatic: Metabolised extensively by CYP3A4/3A5; caution in mild-to-moderate liver disease; avoid in severe hepatic impairment.
Elimination & Renal Adjustment:
Renal: No dose adjustment required in renal impairment (<0.1% excreted unchanged in urine). • Hepatic: Metabolised extensively by CYP3A4/3A5; caution in mild-to-moderate liver disease; avoid in severe hepatic impairment.
Hepatic Impairment Considerations:
Renal: No dose adjustment required in renal impairment (<0.1% excreted unchanged in urine). • Hepatic: Metabolised extensively by CYP3A4/3A5; caution in mild-to-moderate liver disease; avoid in severe hepatic impairment.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: Women, children, and adolescents; pregnancy (Category X teratogen). • Precautions: TERATOGENIC HAZARD: Absorbed percutaneously through skin—women who are pregnant or may become pregnant must NEVER handle crushed, leaking, or broken capsules (causes feminisation of male fetus). Reduces serum PSA by ~50% after 6 months (multiply measured PSA by 2 when screening for prostate cancer).

Key Clinical Precautions: Renal: No dose adjustment required in renal impairment (<0.1% excreted unchanged in urine). • Hepatic: Metabolised extensively by CYP3A4/3A5; caution in mild-to-moderate liver disease; avoid in severe hepatic impairment.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Erectile dysfunction, decreased libido, ejaculatory disorders, gynaecomastia/breast tenderness.
  • High-grade prostate cancer masking if PSA doubling rule is ignored, depressive mood, angioedema.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • CYP3A4 inhibitors (Verapamil, Diltiazem, Itraconazole, Ritonavir) -> decrease dutasteride clearance

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Swallow capsule whole; pregnant women must never touch leaking capsules; takes 3-6 months to shrink the prostate; tell your doctor you take Dutasteride before any PSA blood test; do not donate blood during treatment and for 6 months after stopping.
  • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
  • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
  • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Non-NLEM | Compendia: IP 2026 / NFI 7th Ed 2026 / CDSCO Schedule H / BNF 90th Ed

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Soft Gelatin Capsule / Tablet: 0.5 mg.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.9] (p. 159)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.